

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
7 April 2005 (07.04.2005)

PCT

(10) International Publication Number  
WO 2005/030733 A1

(51) International Patent Classification<sup>7</sup>: C07D 235/08,  
401/12, 405/06, C07F 7/18, A61K 31/4184, A61P 25/00

Laurent, Québec H4S 1Z9 (CA). YANG, Hua [CA/CA];  
AstraZeneca R & D Montréal, 7171 Frederick-Banting, St  
Laurent, Québec H4S 1Z9 (CA).

(21) International Application Number:  
PCT/GB2004/004126

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; As-  
traZeneca AB, S-151 85 Södertälje (SE).

(22) International Filing Date:  
24 September 2004 (24.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0302571-5 26 September 2003 (26.09.2003) SE

(71) Applicant (for all designated States except MG, US): AS-  
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant (for MG only): ASTRAZENECA UK LIM-  
ITED [GB/GB]; 15 Stanhope Gate, London, Greater Lon-  
don W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PAGÉ, Daniel  
[CA/CA]; AstraZeneca R & D Montréal, 7171  
Frederick-Banting, St Laurent, Québec H4S 1Z9 (CA).  
LIU, Ziping [CA/CA]; AstraZeneca R & D Montréal,  
7171 Frederick-Banting, St Laurent, Québec H4S 1Z9  
(CA). TREMBLAY, Maxime [CA/CA]; AstraZeneca R  
& D Montréal, 7171 Frederick-Banting, St Laurent, Québec  
H4S 1Z9 (CA). WALPOLE, Christopher [GB/CA];  
AstraZeneca R & D Montréal, 7171 Frederick-Banting, St

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

Published:


— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF



(IA)



(IB)

(57) Abstract: Compounds of Formulae (IA), (IB) or pharmaceutically acceptable salts thereof; wherein Het, X<sup>1</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, and R<sup>a</sup> are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

WO 2005/030733 A1